This week, Genome British Columbia (BC), which leads genomics innovation on the West Coast of Canada, announced that it has invested $1 million in funding to Aspect Biosystems, a leading Canadian biotechnology company, through its Industry Innovation (I²) funding program. The I² Fund gives commercialization support to innovative companies developing life science technologies that address biological challenges in key economic sectors in BC, such as agriculture, human health, energy and mining, forestry and environment, and fisheries and aquaculture.
“Genome BC’s investment in Aspect Biosystems will provide funds to further their commercialization initiatives including partnership activities as well as the development of their platform technology. Aspect has shown significant commercial traction in a very short period of time and we are pleased to support their continued growth,” said Dr. Tony Brooks, Genome BC’s CFO and Vice President for Entrepreneurship and Commercialization.
Genome BC works with many national and international funding organizations, both public and private, in order to facilitate the integration of genomics into society. Its repayable I² Fund, which is allocated to promising technologies at the early stages of commercial development, also supports digital health and other technologies that help move precision medicine along into clinical practice, and Aspect certainly qualifies.
thumbnail courtesy of 3dprint.com